Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01462084 · ClinicalTrials.gov registry record · NA

Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use

A NA study of Obstructive Sleep Apnea and Chronic Opioid Use, sponsored by ResMed.

Completed
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT01462084 is a NA study of Obstructive Sleep Apnea and Chronic Opioid Use that has completed, run by ResMed. The registered enrollment target is 21 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01462084, a NA study of Obstructive Sleep Apnea and Chronic Opioid Use, has completed, sponsored by ResMed.

COMPLETED
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

Prospective, randomized, blinded, cross-over study assessing the effectiveness of adaptive servo-ventilation (ASV) in treating patients who have obstructive sleep apnea (OSA) complicated by central sleep apnea (CSA) due to the chronic use of opioid medications

Interventions

  • DEVICE Adaptive servo-ventilation (ASV)
  • DEVICE Bi-Level PAP

Study Locations (1)

California

  • Stanford Center for Human Sleep Research - Redwood City

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2011-09
Est. Completion 2012-12
Phase NA

Sponsor

ResMed

25 total trials

What the Registry Record Tells You About NCT01462084

The ClinicalTrials.gov registry entry for NCT01462084 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (90% lower). The listed sponsor is ResMed, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 2 interventions - of which Adaptive servo-ventilation (ASV) is the first listed.

NCT01462084 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01462084 about?

NCT01462084 is a clinical study titled "Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use". Prospective, randomized, blinded, cross-over study assessing the effectiveness of adaptive servo-ventilation (ASV) in treating patients who have obstructive sleep apnea (OSA) complicated by central sleep apnea (CSA) due to the chronic use of opioid medications

What is the current status of trial NCT01462084?

This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2011-09. Estimated completion is 2012-12.

What conditions does trial NCT01462084 study?

This clinical trial studies the following conditions: Obstructive Sleep Apnea, Chronic Opioid Use, Central Sleep Apnea (Diagnosis).

What interventions are being tested in trial NCT01462084?

The interventions under investigation include: Adaptive servo-ventilation (ASV) (DEVICE), Bi-Level PAP (DEVICE).

Who is sponsoring clinical trial NCT01462084?

This trial is sponsored by ResMed, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01462084 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obstructive Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.